Jong Joseph  Kim net worth and biography

Jong Kim Biography and Net Worth

Dr. Jong Kim currently serves as the president, CEO and a director of Inovio Pharmaceuticals. 

Inovio is a pharmaceutical company that develops treatments for cancer and other chronic infectious diseases. The company, which spun out of the University of Pennsylvania Medical School and was known as VGX Pharmaceuticals until 2009, currently has around 300 employees and a market cap of $500 million. 

Dr. Kim co-founded VGX in 2000 and served as its president and CEO until the time of its acquisition by Inovio in 2009, during which time he assumed the roles of president, CEO and director. In his current role, he is working to develop vaccines for developed markets and developing-world markets to combat the world’s top infectious diseases. 

Prior to his career at VGX and Inovio, Dr. Kim spent eight years with Merck & Company Inc. There he led efforts to manufacture and develop a variety of FDA-approved products and developmental therapeutics, including FDA-approved vaccines for hepatitis and developmental vaccines and therapies for HIV AIDS. 

Drawing on his background as an immunologist, Dr. Kim has worked to publish over 100 peer-reviewed scientific papers, holds several patents, and sits on the editorial boards of various scientific review panels. He has been recognized for his contributions to the scientific community by various institutions, with recognition as one of the world’s Top 100 Young Innovators by Technology Review Magazine in 2002, one of the Philadelphia Business Journal’s 40 under 40, and as Ernst & Young’s Entrepreneur of the Year for Greater Philadelphia in 2015. 

Dr. Kim currently sits on the boards of the Council of Korean Americans and the International Vaccine Institute. He is also part of the inaugural class of the Health Innovators Fellowship at the Aspen Institute. As a native of South Korea, he has worked with the World Economic Forum and the Global Agenda Council on Korea to develop new vaccines to protect the world’s poorest populations. 

Dr. Kim holds a Ph.D. in biochemical engineering from the University of Pennsylvania and an M.B.A. in finance from the Wharton School. He received his undergraduate degree from MIT. 

What is Jong Joseph Kim's net worth?

The estimated net worth of Jong Joseph Kim is at least $36,616.32 as of February 1st, 2021. Dr. Kim owns 7,488 shares of Inovio Pharmaceuticals stock worth more than $36,616 as of November 14th. This net worth estimate does not reflect any other assets that Dr. Kim may own. Learn More about Jong Joseph Kim's net worth.

How do I contact Jong Joseph Kim?

The corporate mailing address for Dr. Kim and other Inovio Pharmaceuticals executives is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. Inovio Pharmaceuticals can also be reached via phone at (267) 440-4200 and via email at [email protected]. Learn More on Jong Joseph Kim's contact information.

Has Jong Joseph Kim been buying or selling shares of Inovio Pharmaceuticals?

Jong Joseph Kim has not been actively trading shares of Inovio Pharmaceuticals during the last ninety days. Most recently, Jong Joseph Kim sold 434 shares of the business's stock in a transaction on Wednesday, February 3rd. The shares were sold at an average price of $2,050.56, for a transaction totalling $889,943.04. Following the completion of the sale, the chief executive officer now directly owns 7,488 shares of the company's stock, valued at $15,354,593.28. Learn More on Jong Joseph Kim's trading history.

Who are Inovio Pharmaceuticals' active insiders?

Inovio Pharmaceuticals' insider roster includes Simon Benito (Director), Laurent Humeau (Insider), Peter Kies (CFO), Jong Kim (CEO), Jacqueline Shea (COO), David Weiner (Director), and Lota Zoth (Director). Learn More on Inovio Pharmaceuticals' active insiders.

Jong Joseph Kim Insider Trading History at Inovio Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/3/2021Sell434$2,050.56$889,943.047,488View SEC Filing Icon  
2/1/2021Sell694$2,160.00$1,499,040.007,488View SEC Filing Icon  
7/30/2020Sell694$3,042.72$2,111,647.688,252View SEC Filing Icon  
1/13/2020Buy156$447.84$69,863.047,643View SEC Filing Icon  
6/3/2019Sell14,788$339.84$5,025,553.9213,271View SEC Filing Icon  
5/31/2019Sell3,472$351.36$1,219,921.9213,271View SEC Filing Icon  
5/21/2019Sell694$476.64$330,788.1616,743View SEC Filing Icon  
5/16/2019Sell949$504.00$478,296.0017,437View SEC Filing Icon  
9/12/2018Sell340$773.28$262,915.2016,371View SEC Filing Icon  
4/12/2018Sell720$740.16$532,915.2016,635View SEC Filing Icon  
3/31/2017Sell1,022$941.76$962,478.7215,033View SEC Filing Icon  
8/12/2014Buy1,736$1,304.64$2,264,855.04View SEC Filing Icon  
4/15/2014Buy173$324.00$56,052.0041,429View SEC Filing Icon  
4/2/2013Buy625$72.00$45,000.00View SEC Filing Icon  
3/20/2013Buy416$76.32$31,749.12View SEC Filing Icon  
See Full Table

Jong Joseph Kim Buying and Selling Activity at Inovio Pharmaceuticals

This chart shows Jong Joseph Kim's buying and selling at Inovio Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inovio Pharmaceuticals Company Overview

Inovio Pharmaceuticals logo
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $4.89
Low: $4.86
High: $5.02

50 Day Range

MA: $5.83
Low: $4.95
High: $6.82

2 Week Range

Now: $4.89
Low: $4.20
High: $14.75

Volume

171,773 shs

Average Volume

399,353 shs

Market Capitalization

$126.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83